NewsSource: EClinCloud

Event Preview | Join EClinCloud at "DCT Practice in China: Visiting Pfizer"

2 min readEClinCloud Editorial Team
Article image

Source: EClinCloud.

To promote compliant practice and innovative development in decentralized clinical trials (DCT) and improve clinical trial efficiency and quality, the CMAC DCT Alliance launched the "DCT Practice in China: Visiting Well-Known Pharmaceutical Companies" event series.

DCT Alliance was jointly initiated by CMAC together with well-known domestic and international clinical trial institutions and experts. Taking a patient-centric approach, it brings together members across the full DCT industry-academia-research chain and leverages digital and other innovative technologies to advance academic research and compliant implementation of DCT.






With the continued refinement and widespread adoption of digital tools, the implementation and practice of DCT clinical trial approaches have also become an active area and focus of research.

As a promoter of digital clinical trials in China, EClinCloud has remained dedicated to the research and development of decentralized and intelligent clinical technologies, helping domestic and international pharmaceutical companies and research institutions improve R&D efficiency, reduce clinical research costs and risks, and accelerate new drug launches. In March 2023, leveraging its advanced eCOA system along with its professional medical team and services, EClinCloud supported the regulatory approval and market launch of Raynovent's COVID-19 therapeutic drug.

For this event, Dr. Qin Long, Founder and CEO of EClinCloud, has been invited to attend "DCT Practice in China: Visiting Pfizer" on August 31, where he will share insights on how EClinCloud's eCOA system supported the rapid approval of a new COVID-19 drug and discuss core DCT clinical model application scenarios and compliant practices.

Presentation Details

Date & Time

August 31, 2023, 14:10–14:25

Location

Building 3, Lianhua Business Park, 60 Naxian Road, Pudong New Area, Shanghai

Presentation

Topic

Practice in Action: How EClinCloud's eCOA System Supported the Rapid Approval of a New COVID-19 Drug

Article image

Dr. Qin Long

Founder and CEO, EClinCloud

  • Over 17 years of experience in technology applications within the clinical research industry;
  • An innovative and inspiring leader, and a pioneer in promoting and implementing eCOA, EDC, CTMS, and related technology solutions in clinical trial research in China;
  • Previously served as Asia-Pacific head for several international technology companies, leading rapid regional business growth;
  • An entrepreneur driven by academia and science, dedicated with great passion to shaping new models for future clinical trials.

Article image





About EClinCloud

EClinCloud is a technology company focused on clinical R&D, providing an integrated, interoperable, all-in-one cloud platform for clinical trials (including solutions such as scale design, scale copyright management, linguistic validation, rater training, and data quality analysis across various technology products and solutions including eCOA, CTMS, eTMF, EDC, RTSM, and RM) as well as clinical trial endpoint assessment technologies across therapeutic areas (including central nervous system, ophthalmology, and others). Combining cutting-edge technology with life data, it is building a globally leading, patient-centric SaaS cloud platform for clinical evidence support, helping domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.




Article image



Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.